RT Journal Article
SR Electronic
T1 Practical experience in optimizing Covid-19 therapy in an outpatient setting
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA3677
DO 10.1183/13993003.congress-2021.PA3677
VO 58
IS suppl 65
A1 Roman Bontsevich
A1 Yana Vovk
A1 Liliya Solovyova
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/PA3677.abstract
AB The aim: of study was to analyze the efficacy of modified therapy for mild Сovid-19 in an outpatient setting.Material and methods: at an outpatient visit to a pulmonologist, patients with a probable or confirmed diagnosis of Covid-19 were prescribed a modified treatment regimen. All patients to the standard prescription of umifenofir (in the first 5 days of illness) and anticoagulants in preventive doses (with any degree of lung damage) were added therapy with statin (atorvastatin 40 mg or rosuvastatin 20 mg), a polyenzyme drug (Phlogenzym® or Wobenzym®), ascorbic acid with rutin (450-750 mg each per day), vitamin D (10000 IU - 3 days, then 5000 IU per day), omega-3 fatty acids-1000mg, vitamins A + E (55+100mg bid), zinc (20-50 mg per day).Results: We analyzed 47 treatment outcomes, 55.3% of women, 44.7% of men, average age - 49.5±3.6 years. In the comparison group on standard therapy (Umifenovir in the first 5 days, Interferon alfa nasal, Paracetamol on demand) there were 19 patients (58% of women, 42% of men, average age 50.1±4.7). Only 2 (4.25%) patients in the main group but 3 (15.8%) patients in the comparison group had significant deterioration and subsequent hospitalization, p >0.05. The average duration of the acute symptomatic period (fever, severe weakness) was 5.8 ± 0.74 days, in the comparison group - 9.2 ± 1.04 days, p <0.01. In the main group, a statistically significant improvement in such laboratory parameters was also noted during the week: the level of CRP, ferritin, D-dimer.Conclusions: A statistically significant decrease in symptomatology was revealed in the group with a modified treatment regimen. We believe that further study and comparison of different therapy regimens is required.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3677.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).